{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:48:44Z","timestamp":1779900524932,"version":"3.53.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To evaluate the outcome of Indian children with Guillain-Barr\u00e9 syndrome who received IV immunoglobulin compared with those who did not receive any specific therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Single center, prospective cross-sectional study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Tertiary care neurology teaching hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>Children (\u2264 18 yr old) with Guillain-Barr\u00e9 syndrome were included from a prospectively maintained Guillain-Barr\u00e9 syndrome registry from January 2008 to April 2017. Children were classified into acute inflammatory demyelinating polyradiculoneuropathy, acute motor axonal neuropathy, acute motor-sensory axonal neuropathy, and inexcitable motor nerves based on nerve conduction study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Out of 138 pediatric Guillain-Barr\u00e9 syndrome, 50 received IV immunoglobulin and another 50 age and peak disability matched controls (who did not receive IV immunoglobulin or plasmapheresis) were selected from the same registry for comparison.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>Outcome at 3 and 6 months was defined on the basis of a 0\u201310 Clinical Grading Scale into complete (Clinical Grading Scale &lt; 3), partial (Clinical Grading Scale 3\u20135), and poor (Clinical Grading Scale &gt; 5) recovery. The primary outcome was proportion of patients with complete recovery at 3 and 6 months in IV immunoglobulin and non-IV immunoglobulin groups. Secondary outcomes included in-hospital deaths, duration of mechanical ventilation, and hospital stay. Subgroup analysis was done in acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy groups. The baseline characteristics were similar except for shorter duration of illness and higher proportion of facial palsy in IV immunoglobulin group. Hospital deaths, duration of mechanical ventilation, hospital stay, and outcome at 3 and 6 months were not different between the two groups. Children with acute motor axonal neuropathy had better recovery at 6 months on IV immunoglobulin (58.3% vs 11.1%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.03), but not those with acute inflammatory demyelinating polyradiculoneuropathy (58.3% vs 72.2%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.22). In nonambulatory Guillain-Barr\u00e9 syndrome children, complete recovery at 6 months was similar in IV immunoglobulin and non-IV immunoglobulin group (57.4% vs 57.1%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.98).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In Indian children with Guillain-Barr\u00e9 syndrome, the outcome at 6 months in IV immunoglobulin treated group was similar to non-IV immunoglobulin group. Children with acute motor axonal neuropathy responded better to IV immunoglobulin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pcc.0000000000001935","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T07:37:06Z","timestamp":1555313826000},"page":"652-659","source":"Crossref","is-referenced-by-count":14,"title":["Role of IV Immunoglobulin in Indian Children With Guillain-Barr\u00e9 Syndrome*"],"prefix":"10.1097","volume":"20","author":[{"given":"Jayantee","family":"Kalita","sequence":"first","affiliation":[{"name":"All authors: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mritunjai","family":"Kumar","sequence":"additional","affiliation":[{"name":"All authors: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha K.","family":"Misra","sequence":"additional","affiliation":[{"name":"All authors: Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230823","first-page":"191","article-title":"Guillain-Barr\u00e9 syndrome in children.","volume":"19","author":"Sladky","year":"2004","journal-title":"J Child Neurol"},{"key":"R3-20230823","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/mus.25992","article-title":"Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barr\u00e9 syndrome in India.","volume":"57","author":"Kalita","year":"2018","journal-title":"Muscle Nerve"},{"key":"R4-20230823","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: A systematic review and meta-analysis.","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"R5-20230823","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0387-7604(94)90070-1","article-title":"Guillain-Barr\u00e9 syndrome in children: A cooperative study in Taiwan.","volume":"16","author":"Hung","year":"1994","journal-title":"Brain Dev"},{"key":"R6-20230823","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/PL00007844","article-title":"Distinct pattern of age-specific incidence of Guillain-Barr\u00e9 syndrome in Harbin, China.","volume":"249","author":"Cheng","year":"2002","journal-title":"J Neurol"},{"key":"R7-20230823","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1212\/WNL.33.5.633","article-title":"Guillain-Barr\u00e9 syndrome in the United States, 1978-1981: Additional observations from the national surveillance system.","volume":"33","author":"Kaplan","year":"1983","journal-title":"Neurology"},{"key":"R8-20230823","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1212\/WNL.47.3.668","article-title":"Cytomegalovirus infection and Guillain-Barr\u00e9 syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barr\u00e9 Study Group.","volume":"47","author":"Visser","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 2","key":"R9-20230823","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1086\/513780","article-title":"Epidemiologic and clinical features of Campylobacter jejuni infections.","volume":"176","author":"Blaser","year":"1997","journal-title":"J Infect Dis"},{"key":"R10-20230823","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ana.410440310","article-title":"Acute inflammatory demyelinating polyradiculopathy in children: Clinical and electrodiagnostic studies.","volume":"44","author":"Delanoe","year":"1998","journal-title":"Ann Neurol"},{"key":"R11-20230823","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/adc.74.4.281","article-title":"Natural history and treatment effects in Guillain-Barr\u00e9 syndrome: A multicentre study.","volume":"74","author":"Korinthenberg","year":"1996","journal-title":"Arch Dis Child"},{"key":"R12-20230823","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome.","volume":"19","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20230823","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: A randomized trial.","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"R14-20230823","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: A randomized study.","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"key":"R15-20230823","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group.","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"R16-20230823","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma Exchange\/Sand globulin Guillain-Barr\u00e9 Syndrome Trial Group.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R17-20230823","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"R18-20230823","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"R19-20230823","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/brain\/awq270","article-title":"Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His Majesty\u2019s Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O\u2019Brien for the Guarantors of Brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 Figures.","volume":"133","author":"Compston","year":"2010","journal-title":"Brain"},{"key":"R20-20230823","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0404.1987.tb07902.x","article-title":"Assessment of autonomic dysfunction in Guillain-Barr\u00e9 syndrome and its prognostic implications.","volume":"75","author":"Singh","year":"1987","journal-title":"Acta Neurol Scand"},{"issue":"Pt 4","key":"R21-20230823","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R23-20230823","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/qjmed\/hcv190","article-title":"Outcome of Guillain-Barre syndrome patients with respiratory paralysis.","volume":"109","author":"Kalita","year":"2016","journal-title":"QJM"},{"key":"R24-20230823","first-page":"11","article-title":"Motor conduction velocity and H-reflex in infancy and childhood. II. -Intra and extrauterine maturation of the nerve fibres. Development of the peripheral nerve from 1 month to 11 years of age.","volume":"18","author":"Martinez","year":"1978","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"R25-20230823","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1542\/peds.34.5.708","article-title":"Conduction velocity of motor nerves in infants and children.","volume":"34","author":"Dunn","year":"1964","journal-title":"Pediatrics"},{"key":"R27-20230823","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"R28-20230823","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1090-3798(97)80004-9","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barr\u00e9 syndrome.","volume":"1","author":"Kanra","year":"1997","journal-title":"Eur J Paediatr Neurol"},{"key":"R30-20230823","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: Critical reassessment of effectiveness and cost-efficiency.","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"R31-20230823","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CND.0000000000000176","article-title":"Outcome of Guillain-Barr\u00e9 syndrome in tertiary care centers in Thailand.","volume":"19","author":"Kulkantrakorn","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"R32-20230823","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jfma.2012.08.011","article-title":"Clinical and electrophysiologic features of childhood Guillain-Barr\u00e9 syndrome in Northeast China.","volume":"113","author":"Ye","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"R33-20230823","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0022-510X(93)90324-R","article-title":"Severe axonal degeneration in acute Guillain-Barr\u00e9 syndrome: Evidence of two different mechanisms?","volume":"116","author":"Feasby","year":"1993","journal-title":"J Neurol Sci"},{"key":"R34-20230823","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jnnp-2011-300309","article-title":"Antiganglioside antibodies are associated with axonal Guillain-Barr\u00e9 syndrome: A Japanese-Italian collaborative study.","volume":"83","author":"Sekiguchi","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R35-20230823","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.expneurol.2011.11.039","article-title":"Dysfunction of nodes of Ranvier: A mechanism for anti-ganglioside antibody-mediated neuropathies.","volume":"233","author":"Susuki","year":"2012","journal-title":"Exp Neurol"},{"key":"R36-20230823","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases.","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130478-201907000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:47:17Z","timestamp":1692838037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130478-201907000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000001935","relation":{},"ISSN":["1529-7535"],"issn-type":[{"value":"1529-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}